B. Riley raised the firm's price target on Journey Medical to $12 from $11 and keeps a Buy rating on the shares. Journey Medical delivered strong Q4 execution, with Emrosi generating $14.7M in FY25 revenues over nine months and prescription volumes growing about 50% sequentially, supporting a robust exit into 2026, the analyst tells investors in a research note.
